First Wave Biopharma Stock Profit Margin
| FWBIDelisted Stock | USD 0.61 0.03 4.69% |
First Wave BioPharma fundamentals help investors to digest information that contributes to First Wave's financial success or failures. It also enables traders to predict the movement of First Stock. The fundamental analysis module provides a way to measure First Wave's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to First Wave stock.
First |
First Wave BioPharma Company Profit Margin Analysis
First Wave's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, First Wave BioPharma has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
First Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses First Wave's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of First Wave could also be used in its relative valuation, which is a method of valuing First Wave by comparing valuation metrics of similar companies.First Wave is currently under evaluation in profit margin category among its peers.
First Fundamentals
| Return On Equity | -0.15 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 72.56 M | |||
| Shares Outstanding | 2.03 M | |||
| Shares Owned By Insiders | 5.66 % | |||
| Shares Owned By Institutions | 1.46 % | |||
| Number Of Shares Shorted | 46.6 K | |||
| Price To Book | 1.87 X | |||
| EBITDA | (15.74 M) | |||
| Net Income | (15.79 M) | |||
| Cash And Equivalents | 1.16 M | |||
| Cash Per Share | 0.83 X | |||
| Total Debt | 826.84 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | 7.99 X | |||
| Cash Flow From Operations | (12.38 M) | |||
| Short Ratio | 1.02 X | |||
| Earnings Per Share | (47.88) X | |||
| Target Price | 36.0 | |||
| Beta | 1.28 | |||
| Market Capitalization | 5.99 M | |||
| Total Asset | 6.88 M | |||
| Retained Earnings | (184.33 M) | |||
| Working Capital | 1.82 M | |||
| Net Asset | 6.88 M |
About First Wave Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze First Wave BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of First Wave using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of First Wave BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in First Stock
If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |